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Background and aims: Oesophageal adenocarcinoma frequently develops on a background of
metaplastic Barrett’s epithelium. The development of malignancy is accompanied by genetic alterations,
which may be promising biomarkers of disease progression.
Methods: A case control study was conducted nested within a large unselected population based cohort of
Barrett’s patients. Incident oesophageal malignancies and high grade dysplasias were identified. For each
case up to five controls were matched on age, sex, and year of diagnosis. Biopsies from the time of
diagnosis of Barrett’s epithelium were stained immunohistochemically for TP53, cyclin D1, cyclooxygenase
2 (COX-2), and b-catenin proteins.
Results: Twenty nine incident oesophageal malignancies and six cases of high grade dysplasia were
identified. The odds of diffuse or intense TP53 staining were substantially elevated in biopsies from patients
who developed oesophageal adenocarcinoma compared with controls (odds ratio (OR) 11.7 (95%
confidence interval (CI) 1.93, 71.4)). This difference was also present when all cases were considered (OR
8.42 (95% CI 2.37, 30.0). Despite the association with TP53 staining, only 32.4% of cases had an initial
biopsy showing diffuse/intense TP53 staining. There were no significant associations between cyclin D1,
COX-2, or b-catenin staining and case control status. The OR for positive staining for both TP53 and
COX-2 was markedly increased in cases compared with controls (OR 27.3 (95% CI 2.89, 257.0))
although only 15% of cases had positive staining for both markers.
Conclusions: Immunohistochemical detection of TP53 expression is a biomarker of malignant progression
in Barrett’s oesophagus but sensitivity is too low to act as a criterion to inform endoscopic surveillance
strategies. Additional biomarkers are required which when combined with TP53 will identify, with
adequate sensitivity and specificity, Barrett’s patients who are at risk of developing cancer.
O
esophageal adenocarcinoma (OA) is commonly asso-
ciated with a precancerous condition termed Barrett’s
oesophagus (BO) in which the normal squamous
epithelium of the distal oesophagus is replaced by a
specialised intestinal metaplasia (SIM) characterised by the
presence of goblet cells.1 BO patients have an elevated risk of
adenocarcinoma,1 2 a malignancy for which five year survival
following diagnosis is generally less than 15%.3 4
Consequently, interest has focused on surveillance by upper
gastrointestinal endoscopy in an attempt to provide earlier
detection and more effective treatment. Several studies have
shown that patients diagnosed with OA within a BO
surveillance programme have earlier stage disease and longer
survival times than patients diagnosed outside such pro-
grammes5–7 but these studies may be subject to length and
lead time bias. Randomised controlled trial evidence of the
effectiveness of surveillance programmes in reducing mor-
tality in BO patients is not available. The relatively low
incidence of OA among BO patients,8 9 competing mortalities,
and loss to follow up in surveillance programmes10 have led to
questions concerning their effectiveness,11 12 particularly in
light of competing economic pressures on healthcare sys-
tems.13 14
Surveillance of BO is commonly undertaken both in the
USA and Europe.15–17 Identification of BO patients at highest
risk of development of adenocarcinoma using biomarkers
may permit current surveillance strategies to be more
individually tailored and, presumably, more cost effective. A
number of genetic alterations have been associated with the
metaplastic and dysplastic changes that represent early
stages in the natural history of OA.1 18 In particular,
aneuploidy, loss of heterozygosity (LOH) on chromosome
9p21 and 17p, hypermethylation and mutation of CDKN2
(p16), TP53 mutations, overexpression of cyclin D1 and
cyclooxygenase 2 (COX-2), and nuclear accumulation of
b-catenin have all been reported in BO tissue.2 19 20
While there are many cross sectional studies of genetic
alterations in relation to the development of OA2 there are
fewer longitudinal studies of BO patients that have examined
these alterations in biopsy specimens in advance of the later
stages of the disease.1 2 The former would be termed phase 1
and 2 studies and the latter as phase 3 and 4 in the recently
proposed classification system by the USA National Cancer
Institute’s Early Detection Research Network.21 In this
context, Reid and colleagues22 have reviewed biomarkers
commonly applied to BO and OA, notably dysplasia, ploidy,
TP53, cyclin D1, and p16 status. In a case control analysis
nested within a cohort of 350 Barrett’s patients in Leeds, UK,
cyclin D1, and to a lesser extent TP53, immunostaining in
biopsies of BO patients was associated with an increased risk
of progression to adenocarcinoma.23 In a prospective study of
269 patients in Seattle, USA, 17p LOH was also strongly
associated with progression in BO patients.24 However,
subjects in both of these studies were drawn from selected
Abbreviations: OA, oesophageal adenocarcinoma; BO, Barrett’s
oesophagus; SIM, specialised intestinal metaplasia; LOH, loss of
heterozygosity; COX-2, cyclooxygenase 2; H&E, haematoxylin and
eosin; NIBR, Northern Ireland Barrett’s Oesophagus Register; TBS, Tris
buffered saline; OR, odds ratio
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populations of BO patients with the attendant risks of
selection bias.
In this study, we examined whether altered expression of
four candidate biomarkers—namely, cyclin D1, TP53, COX-2,
and b-catenin—was associated with a risk of oesophageal
malignancy using a case control design nested within a large
unselected population based cohort of BO patients. TP53 and
cyclin D1 were selected because of their promise in earlier
longitudinal studies22–24 while COX-2 was studied because of
the documented increase in expression during progression
from BO to dysplasia and OA.25–27 Inclusion of b-catenin was
based on earlier observations that nuclear accumulation of
this protein was common in OA28 and that promoter
hypermethylation of the APC gene was frequent in BO
patients, suggesting a potential mechanism for dysregulation
of the WNT APC b-catenin pathway and the observed nuclear
translocation of b-catenin.2 29 Increased nuclear b-catenin
could also be a consequence of reduced expression of
E-cadherin which has been reported to occur in Barrett’s
metaplasia.30
MATERIALS AND METHODS
Patient selection
A nested case control study was conducted within a
population based cohort of BO patients, the Northern
Ireland Barrett’s Oesophagus Register (NIBR).8 31 The NIBR
comprises every adult identified within Northern Ireland (NI,
population 1.7 million) between January 1993 and December
1999 as having oesophageal columnar epithelium. The
register was constructed by examining pathology reports
relating to all oesophageal biopsies taken in NI during this
period. BO was defined histologically as the presence of SIM
(including the presence of goblet cells), irrespective of
whether Barrett’s mucosa was reported visually by the
endoscopist. Biopsies stated (by the endoscopist) as having
been taken at the oesophagogastric junction were excluded.
Infrequent provision of data on BO segment length precluded
its incorporation into the definition but these data were
recorded where available.
Individual patients were identified within the dataset and
were followed up for death and oesophageal malignancy
until the end of 2000 by matching with death files from the
NI Registrar General’s Office and the NI Cancer Registry
database of incident cancers. Cases were defined as patients
within NIBR who developed OA, or undifferentiated/unspec-
ified oesophageal carcinoma during the follow up period and
at least a minimum of six months from their first biopsy
showing BO as in our previous study.23 Squamous cell
tumours of the oesophagus were not included. Patients
undergoing treatment (oesophagectomy or ablative treat-
ment) for high grade dysplasia within the same period were
also identified and included as cases for certain analyses. For
each of the incident cases, five control patients who did not
develop oesophageal carcinoma during the follow up period
were selected from the register. Controls had to have biopsies
that showed evidence of SIM and by preference those with
long segment columnar lined epithelium were selected.
Controls were also matched with cases on age (within five
years), sex, and year of diagnosis; controls had a period of
follow up of at least as long as that of their respective case.
Ethics approval for the study was granted by the Research
Ethics Committee of Queen’s University, Belfast.
Histology
The original oesophageal biopsies on which the classification
of BO was made were obtained for each of the cases and
controls from the four pathology laboratories in the province
(Belfast Link Laboratories, Antrim Hospital, Craigavon Area
Hospital, and Altnagelvin Hospital). New sections were
prepared from each histology block. One section of each
biopsy was stained with haematoxylin and eosin (H&E) and
examined for confirmation of SIM, as defined by the
presence of goblet cells. Only biopsies containing goblet cells
were used for immunohistochemistry. H&E sections were
scored by consensus by two histopathologists (MS and
DMcM) for the presence and grade of dysplasia according
to a modification of the Vienna classification: 0 = no
dysplasia, 1 = indefinite for dysplasia, 2 = low grade dyspla-
sia, 3 = high grade dysplasia, and 4 = intramucosal adeno-
carcinoma. Inflammation was also graded, where 0 = no
inflammation, 1 = mild inflammation, 2 = moderate inflam-
mation, and 3 = severe inflammation.
The remaining sections were shipped to Leeds for
immunohistochemical staining for cyclin D1, TP53, COX-2,
and b-catenin. Investigators in Leeds were blinded as to the
case and control status of the slides.
Immunohistochemistry
The protocol for immunohistochemistry was similar for each
of the four markers examined. Initially, sections were
dewaxed in xylene before rehydration through alcohol to
water. Endogenous peroxidase activity was then blocked by
immersing the slides in methanol containing 2% hydrogen
peroxide for 30 minutes. After washing in water, slides were
rinsed in Tris buffered saline (TBS) (50 mM Tris, pH 7.6)
prior to antigen retrieval by pressure cooking (see specific
conditions below). Staining was performed on a Sequenza
Work Station (ThermoShandon, Runcorn UK). Non-specific
binding was blocked using a casein solution (SP-5020 Vector
Labs) as per the manufacturer’s instructions followed by
treatment with the Avidin-Biotin Blocking kit (SP-2001;
Vector Labs., Peterborough, UK). Sections were then incu-
bated in primary antibody (see specific conditions below)
diluted in TBS with 0.01% Tween 20.
After incubation with primary antibody, slides were
washed twice with TBS prior to incubation with the
biotinylated secondary antibody for 30 minutes at room
temperature. Slides were washed twice with TBS to remove
secondary antibody and stained with ABC solution for
30 minutes (Vector Stain Elite ABC kits, PK-6102; Vector
Labs). Slides were removed from the Sequenza Work Station
and staining was developed by addition of a working
concentration of 0.025% w/v diaminobenzidine substrate in
TBS. Slides were rinsed in TBS, placed into a copper sulphate
solution for five minutes to enhance staining, washed in
water, lightly counterstained with haematoxylin, and then
dehydrated, cleared, and mounted in DPX for evaluation.
Matched case and control sections were run together,
coded, in a single batch to minimise any risk of bias in
immunostaining between the two groups. The same positive
and negative control sections for each biomarker were also
included with each batch of immunostaining on the test
sections to monitor any batch-to-batch variations in staining.
The controls comprised tissue sections from the same tissue
blocks throughout, obtained from histologically normal or
carcinoma lung tissue, where the negative or positive staining
for the various antigens was validated in preliminary
experiments; optimal conditions for signal to noise ratio of
immunostaining were also determined on these sections.
Specific antibodies and conditions for each staining process
were:
N TP53 (Novocastra NCL-L-TP53-D07; mouse monoclonal
IgG2b raised against a recombinant human wild-type p53
protein): 90 seconds antigen retrieval; 1:100 dilution
primary antibody, one hour at 25 C˚; 1:200 dilution
secondary antibody.
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N Cyclin D1 (Novocastra NCL-L-CYCLIND1-GM; mouse
monoclonal IgG2a raised against a prokaryotic fusion
protein corresponding to the human cyclin D1 molecule):
60 seconds antigen retrieval; 1:50 dilution primary anti-
body, one hour at 25 C˚; 1:100 dilution secondary antibody.
N b-catenin (Transduction Laboratories, BD Pharmingen,
G10153; mouse monoclonal IgG1, generated against the C
terminal of mouse b-catenin): 90 seconds antigen retrie-
val; 1:240 dilution primary antibody, one hour at 25 C˚;
1:100 dilution secondary antibody.
N COX-2 (Cayman Chemicals, Alexis Biochemicals, 160112;
mouse monoclonal raised against a synthetic peptide
corresponding to COX-2): 90 seconds antigen retrieval;
1:250 dilution primary antibody, overnight at 4 C˚; 1:100
dilution secondary antibody.
Evaluation of immunohistochemical staining
The stained sections were independently scored for specific
staining within columnar mucosa by the two histopathol-
ogists blinded to the case control status of the sections.
Nuclear staining was evaluated for TP53, cyclin D1, and
b-catenin using a modification of a method previously
applied to a series of gastro-oesophageal tumours where
TP53 mutation status was known.32 With regard to b-catenin,
only nuclear positivity was assessed.28 Biopsies were assigned
a score of 0–3 based on the following criteria: 0 = no positive
cells or only occasional scattered positive cells (no staining);
1 =,10% of epithelial cells positive (focal staining); 2 = 10–
50% positive (diffuse staining); and 3 =.50% of epithelial
cells positive or confluent groups of positively stained glands
(intense staining). COX-2 sections were examined for the
presence of cytoplasmic staining and were also scored 0–3 by
assessing both staining intensity and the proportion of
positive epithelial cells (stromal cells were not considered)
in a modification of a scoring system previously described33:
0 = no positive cells or occasional scattered weakly positive
cells; 1 =,10% of epithelial cells with weak to moderate
positive staining; 2 = 10–50% weakly or moderately positive
or ,10% strongly positive; and 3 =.50% moderately to
strongly positive. Scores for sections containing more than
one tissue fragment were defined according to the highest
scoring fragment. The location of staining (that is, in crypts,
on the surface, or both) was also recorded for each marker.
Statistical methods
All statistical analyses were performed using STATA version
8. The kappa statistic was used to assess agreement between
the histopathologists assessment of immunohistochemical
staining. Analyses were initially performed with cases
defined as patients who developed high grade dysplasia,
undifferentiated/unspecified carcinoma, and definite OA.
Subsequent analyses excluded firstly all high grade dysplasia
patients and then patients with undifferentiated/unspecified
A B
C D
E F
Figure 1 Immunohistochemical
staining for TP53 and cyclin D1. (A–D)
Examples of TP53 staining graded as 0
(none), + (focal), ++ (diffuse), and +++
(intense), respectively. (E, F) Examples
of staining for cyclin D1, classified as 0
(none) and ++ (diffuse), respectively. As
described in the materials and methods,
only staining in the columnar epithelium
was considered in relation to cancer
risk; low levels of TP53 and cyclin D1
staining in the basal layer of the normal
squamous epithelium in (A) and (E),
respectively, was expected and serves
to illustrate that the immunostaining
reaction was working in these sections.
Sections processed in the absence of
primary antibody showed staining of
similar background to that classified
here as ‘‘0’’ or no staining.
Magnification6200.
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carcinoma. Matched controls for these patients were also
excluded. Conditional logistic regression models were devel-
oped with case control status as the dependent variable and
staining for the molecular markers as explanatory variables.
No staining (grade 0) was used as the reference category and
the diffuse (grade 2) and intense (grade 3) categories were
combined because of small numbers in each of these
categories. The analyses were repeated with grades 0 and 1
combined as the reference category to permit the additional
comparison of weak (0, 1 grade) versus strong (2, 3 grade)
staining. The potential confounding effect of the conditions
in which the biopsies were stored on the results of
immunohistochemical staining was addressed by including
pathology laboratory as an explanatory variable in all
statistical models.
RESULTS
Between January 1993 and December 1999, pathologists
reported on 15 670 oesophageal biopsy specimens from
patients who underwent upper gastrointestinal endoscopy
within hospitals in NI. All of these reports were examined
and 4955 biopsies (oesophagogastric biopsies excluded) from
2969 patients (1701; 57.3% male) showed oesophageal
columnar epithelium. In 1670 (56.2%) of these patients,
SIM was reported to be present in at least one oesophageal
biopsy. Mean period of follow up in the whole cohort was
3.7 years (range 0–8.0); it was 2.3 years (range 0.5–7.4) in
the cases and 3.9 years (range 1.1–7.8) in controls.
Twenty two patients developed OA a minimum of six
months after the date of their first biopsy showing BO; one
patient was diagnosed with an oesophageal adenosquamous
carcinoma (treated as OA in the analyses) and a further six
patients developed undifferentiated/unspecified carcinomas
of the oesophagus, giving a total of 29 incident oesophageal
malignancies (22; 76%, in men) within the cohort. Review of
pathology specimens did not result in further classification of
the six undifferentiated/unspecified carcinomas mentioned
above. An additional four patients underwent oesophagect-
omy for high grade dysplasia within their segment of BO and
two further patients had ablative treatment for BO by laser.
Review of the pathology specimens of these patients
confirmed high grade dysplasia without malignancy and
they were included in the study to yield a total of 35 cases.
All but one of the original pathology specimens relating to
the 35 cases were obtained; the missing biopsy was from a
patient who subsequently developed OA. Twelve selected
control specimens (6.9%) could not be obtained but speci-
mens were available for a minimum of three controls per
case. Insufficient material in some biopsy specimens meant
that COX-2 staining was not performed on one further
control and b-catenin staining was not performed on one
further case and two further controls.
SIM was confirmed to be present in at least one biopsy
fragment from every available case and control specimen.
Cyclin D1, TP53, COX-2, and b-catenin staining scores
ascribed independently by the histopathologists agreed in
all but 4.6%, 8.6%, 9.6%, and 7.1% of the specimens,
respectively (kappa statistics 0.92, 0.86, 0.83 and 0.85,
respectively), and in all cases the scores differed by only
one category. The lowest category was used in the analyses
when the categories ascribed by the histopathologists
differed. Examples of the staining for TP53 and cyclin D1
are presented in fig 1. Staining in the columnar epithelium
only was the subject of this study; some positive staining in
the basal cell layer of the normal squamous epithelium was
visible.
Comparison of cases and controls on matching criteria
showed that males represented 77.1% of cases (27 males,
eight females) and controls (135 males, 40 females) and that
age did not significantly differ between the groups (68.0
(10.6) years in cases and 67.1 (10.5) years in controls;
t = 0.48, p = 0.95). In addition, the number of biopsy
fragments did not differ significantly between slides prepared
from cases and controls (4.50 (2.3) and 4.39 (2.1),
respectively; t = 0.28, p = 0.5). The characteristics of oeso-
phageal biopsies are shown in table 1. Only four specimens
showed evidence of dysplasia; one showed high grade
dysplasia and this patient developed adenocarcinoma within
Table 1 Characteristics of initial oesophageal biopsies
Biopsy characteristic No of cases* (%) No of controls (%)
Dysplasia
None or indefinite 33 (97.1) 161 (98.8)
Low grade 0 2 (1.2)
High grade 1 (2.9) 0
Inflammation
None or mild (0, 1) 25 (73.5) 106 (65.0)
Moderate or severe (2, 3) 9 (26.5) 57 (35.0)
Cyclin D1 staining
Grade 0 (none) 5 (14.7) 29 (17.8)
Grade 1 (focal) 19 (55.9) 70 (42.9)
Grade 2 (diffuse) 8 (23.5) 52 (31.9)
Grade 3 (intense) 2 (5.9) 12 (7.4)
TP53 staining
Grade 0 (none) 13 (38.2) 85 (52.1)
Grade 1 (focal) 10 (29.4) 59 (36.2)
Grade 2 (diffuse) 8 (23.5) 17 (10.4)
Grade 3 (intense) 3 (8.8) 2 (1.2)
COX-2 staining
Grade 0 7 (20.6) 28 (17.3)
Grade 1 18 (52.9) 106 (65.4)
Grade 2 8 (23.5) 28 (17.3)
Grade 3 1 (2.9) 0
b-catenin staining
Grade 0 (none) 21 (63.6) 105 (65.2)
Grade 1 (focal) 11 (33.3) 54 (33.5)
Grade 2 (diffuse) 1 (3.0) 2 (1.2)
Grade 3 (intense) 0 0
*Incident oesophageal malignancy and high grade dysplasia.
COX-2, cyclooxygenase 2.
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a year. None of the specimens from cases showed low grade
dysplasia. Modest or severe inflammation was more common
in control specimens (35%) than case specimens (26.5%) but
the difference was not statistically significant (x2 5.60, df 3,
p = 0.13).
The results of staining for cyclin D1, TP53, COX-2, and
b-catenin are shown in table 1 and the results of the paired
(conditional) logistic regression analyses are shown in table 2.
Cyclin D1 staining was observed in .10% of cells (grade 2
and 3, diffuse or intense) in 39.3% of controls and in 29.4% of
cases. Staining was mainly restricted to the crypts but was
also seen on the surface of the epithelium in cases where
strong staining occurred (see fig 1). Immunohistochemistry
for COX-2 revealed the two strongest categories of staining to
be present in 17.3% of controls and in 26.4% of cases. The
pattern of COX-2 staining was similar to cyclin D1 and in the
case of both markers there was no difference in the patterns
between cases and controls. In some biopsies, staining for
COX-2 was negative in the mucosa but strongly positive in
inflammatory debris and granulation tissue on the surface of
the oesophageal biopsy.
Diffuse or intense TP53 staining was observed in 11.6% of
controls and in 32.3% of cases. In just over half (52%) of
samples, TP53 staining was seen in both the crypts and
surface, and in the other samples staining was limited to the
crypts; there was no difference between cases and controls in
the distribution of staining. The majority of sections were
negative for strong (grades 2 or 3) nuclear b-catenin staining.
In almost all samples (96%) in both cases and controls,
b-catenin staining was confined to the crypts.
The odds ratio for biopsies from patients who developed
incident OA showing diffuse or intense TP53 staining was
substantially elevated compared with controls (odds ratio
(OR) 11.7 (95% confidence interval (CI) 1.93, 71.4)). This
elevated OR was also seen when all oesophageal malignan-
cies or all cases, including high grade dysplasias, were
included in the analysis (table 2). No increased risk was
associated with focal TP53 staining, defined as ,10% cells
positive for this marker. When diffuse or intense staining was
compared with none or focal staining, the OR (95% CI) for
patients who developed definite OA showing TP53 staining
was 9.28 (1.78, 48.3).
The odds of positive staining for cyclin D1 was not raised in
cases compared with controls, either for focal staining or
diffuse/intense staining. This was true when all oesophageal
malignancies and high grade dysplasias were considered (OR
for diffuse/intense staining v no staining 0.93 (95% CI 0.21,
4.22)) or when the analysis was restricted to those with
Table 2 Odds of cases compared with controls showing evidence of staining for markers in the initial oesophageal biopsies
Marker
Oesophageal malignancy and
high grade dysplasia Oesophageal malignancy Oesophageal adenocarcinoma
Cases Controls
OR
(95% CI) Cases Controls
OR
(95% CI) Cases Controls
OR
(95% CI)
Cyclin D1
None 5 29 1.00 4 19 1.00 3 17 1.00
Focal 19 70 1.66 (0.44, 6.20) 15 58 1.14 (0.30, 4.28) 11 44 1.26 (0.27, 5.81)
Diffuse/intense 10 64 0.93 (0.21, 4.22) 9 59 0.65 (0.14, 2.94) 8 47 0.81 (0.14, 4.58)
Diffuse/intense v none/focal 0.59 (0.24, 1.48) 0.58 (0.22, 1.52) 0.66 (0.22, 1.99)
TP53
None 13 85 1.00 10 66 1.00 8 60 1.00
Focal 10 59 1.65 (0.59, 4.63) 8 53 1.48 (0.47, 4.68) 6 34 1.57 (0.43, 5.67)
Diffuse/intense 11 19 8.42 (2.37, 30.0) 10 17 11.1 (2.32, 52.7) 8 14 11.7 (1.93, 71.4)
Diffuse/intense v none/focal 6.34 (2.11, 19.1) 8.59 (2.22, 33.3) 9.28 (1.78, 48.3)
COX-2
None 7 28 1.00 6 22 1.00 5 19 1.00
Grade 1 18 106 0.72 (0.25, 2.08) 14 90 0.58 (0.18, 1.87) 11 74 0.53 (0.15, 1.83)
Grade 2/3 9 28 1.62 (0.36, 7.30) 8 23 1.65 (0.30, 9.05) 6 14 1.68 (0.26, 10.7)
Grade 2/3 v grade 0/1 2.22 (0.72, 6.79) 2.78 (0.77, 9.95) 3.03 (0.71, 12.9)
b-catenin
None 21 105 1.00 15 85 1.00 11 67 1.00
Focal 11 54 1.05 (0.45, 2.44) 11 42 1.33 (0.54, 3.28) 9 37 1.46 (0.55, 3.95)
diffuse/intense 1 2 2.40 (0.19, 29.7) 1 2 2.43 (0.20, 30.3) 1 2 2.22 (0.17, 28.1)
Diffuse/intense v none/focal 2.37 (0.19, 29.2) 2.27 (0.18, 28.0) 2.04 (0.16, 25.8)
Oesophageal malignancy refers to adenocarcinomas and patients with undifferentiated/unspecified carcinoma.
Reference category in each analysis is no staining.
COX-2, cyclooxygenase 2; OR (95% CI), odds ratio (95% confidence interval).
Table 3 Effect of the combination of biomarkers on the proportion of cases that were
biomarker positive and the odds of biomarker positivity in cases compared with controls
Combination of biomarkers
No (%) biomarker positive
OR (95% CI)Cases* Controls
TP53+ve 11 (32.4%) 19 (11.7%) 6.34 (2.11, 19.1)
TP53+ve or cyclin D1+ve 17 (50%) 68 (41.7%) 1.68 (0.71, 3.98)
TP53+ve or COX-2+ve 15 (44.1%) 44 (27.2%) 2.67 (1.10, 6.51)
TP53+ve or b-catenin+ve 11 (33.3%) 18 (11.2%) 6.23 (2.06. 18.8)
TP53+ve and cyclin D1+ve 4 (11.8%) 15 (9.2%) 1.51 (0.41, 5.61)
TP53+ve and COX-2+ve 5 (14.7%) 3 (1.8%) 27.3 (2.89, 257.0)
TP53+ve and b-catenin+ve 1 (2.9%) 2 (1.2%) 2.48 (0.20, 30.3)
*Figures relate to oesophageal adenocarcinoma, undifferentiated/unspecified oesophageal carcinomas, and high
grade dysplasia
Biomarker positivity = diffuse/intense (grade 2/3) staining.
COX-2, cyclooxygenase 2; OR (95% CI), odds ratio (95% confidence interval).
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definite OA (OR 0.81 (95% CI 0.14, 4.58)) (table 2). Exclusion of
only high grade dysplasia cases from the analysis did not
significantly alter the results. When the two lowest categories of
staining were used as the reference and compared with diffuse/
intense staining, there was still no significant difference
between cases and controls (OR 0.66 (95% CI 0.22, 1.99)).
Moderate elevation in the odds of positive staining for
COX-2 or b-catenin was seen in cases (especially when
restricted to definite OA) but statistical significance was not
reached (table 2).
Despite the high odds ratio for TP53 staining in cases
compared with controls, only 11 of 34 patients (32.4%) who
developed oesophageal malignancy or high grade dysplasia
had an initial biopsy showing diffuse/intense TP53 staining.
This percentage was similar when considering all patients
who developed oesophageal malignancy (10 of 28; 25.7%) or
only those who developed OA (eight of 22 patients (36.3%)).
The effect of combining biomarkers on the proportion of
cases that were biomarker positive (grade 2/3 staining) and
the odds of biomarker positivity in cases compared with
controls are shown in table 3. Staining positively for either
TP53 or one of the other biomarkers increased the proportion
of cases who were classified as ‘‘biomarker positive’’ but
reduced the strength of the association between biomarker
positivity and risk of malignancy. On the other hand, biopsies
from cases were much more likely to stain positively for both
TP53 and COX-2 (OR 27.3 (95% CI 2.89, 257.0)) but only 15%
of cases were positive for both biomarkers.
DISCUSSION
Four potential biomarkers for predicting progression of BO to
OA were examined in a nested case control study within a
population based cohort of BO patients. All patients with SIM
of the oesophagus diagnosed within NI during the study
period were included and population based registers utilised
to identify deaths and incident oesophageal malignancies
within this group. Patients leaving NI may have been lost to
follow up but emigration is unusual among the age group
studied. The rate of oesophageal malignancy among patients
in the NIBR is 0.4% per year for patients with SIM.8 It is
important to note that this is a population based register of
all Barrett’s patients in a specific community and not a
surveillance cohort. As such, questions concerning the stage
of diagnosed cancers and clinical effectiveness of the register
are not relevant.
Particular strengths of the study were the relatively high
number of cases in comparison with previous longitudinal
studies of BO and OA, the unselected population, the fact
that the analysis was applied to biopsies collected under the
varied protocols that typify much of this field of clinical
practice, and the use of immunostaining that is feasible
within a routine setting using archival biopsies. Thus the
study design approximates to what would be encountered in
translating research findings into clinical practice; in this
sense the results have relevance to a broad range of clinical
settings rather than only to high intensity surveillance in
specialised facilities.
There are some weaknesses in design, in particular the
relatively short follow up (mean follow up 3.7 years) which
means it is highly unlikely that all oesophageal malignancies
that will occur within the cohort of BO patients have
occurred during follow up. In addition, oesophageal biopsy
protocols were not systematic. While this means the results
may be more readily generalised, this does present potential
problems. Firstly, individuals within the cohort could be
misclassified with respect to the presence of SIM. However,
all patients with columnar oesophageal mucosa were
followed up, irrespective of whether SIM was detected or
not, and SIM was retrospectively confirmed to be present in
at least one biopsy fragment from every available case and
control specimen in the nested case control study. Secondly,
differences in biopsy protocol could affect the number of
biopsies and hence the chances of identifying positive
immunostaining. However, there were no significant differ-
ences in numbers of biopsies on the slides between cases and
controls, making a systematic bias unlikely. Thirdly, it is
possible that some of the biopsies evaluated may have been
cardiac rather than oesophageal SIM. It is uncertain what
effect this may have on the biomarker-disease associations.
However, the likelihood of including cardiac SIM was
minimised by excluding biopsies taken from the oesophago-
gastric junction. Also, this issue reflects a common problem
in the clinical setting and the findings may therefore be more
relevant to practice than studies employing very strict biopsy
protocols that are unlikely to be routinely applied.
Although all of the selected biomarkers are involved in
pathways previously implicated in the pathogenesis of BO
and OA, only staining for TP53 protein was significantly
associated with the risk of malignant progression. The
original biopsy specimens from patients who developed OA,
undifferentiated/unspecified carcinoma, or high grade dys-
plasia were eight times more likely to show diffuse/intense
staining for TP53 than were specimens from individuals who
did not develop these outcomes. When the more specific
outcome of histologically confirmed OA was employed,
biopsies from cases were 11 times more likely than controls
to show TP53 staining. The OR for diffuse/intense COX-2
staining was also elevated, especially in confirmed adeno-
carcinomas (threefold increase), although this result was not
statistically significant. Staining for cyclin D1 was not
associated with case control status and nuclear b-catenin
staining was uncommon in cases and controls.
Few other longitudinal studies have examined the relation-
ship between TP53 protein immunostaining in BO and the
risk of OA. Three studies have shown that detection of TP53
in the presence of low grade dysplasia is a risk factor for
progression to high grade dysplasia or cancer.34–36 We
previously observed a threefold increased risk, albeit not
statistically significant, of progression to adenocarcinoma in
BO patients staining positively for TP53.23 Combining data for
that study and the current one results in a statistically
significant pooled OR of 4.97 (95% CI 1.73, 14.3). Using a
molecular approach, Reid and colleagues24 showed that BO
patients with 17p LOH (at the TP53 locus) had a 16-fold
higher risk of progression to cancer than those without this
abnormality. Neither of the latter studies were undertaken
from a population perspective but both are consistent with an
elevated risk of malignant progression in BO patients with
TP53 abnormalities. The current study indicates that TP53
overexpression without dysplasia is predictive of cancer risk
as only one of the 11 patients whose initial biopsies were
TP53 positive, and who developed malignancy, also had
dysplastic changes (high grade dysplasia).
One important question with regard to TP53 immuno-
staining is exactly what does the measure indicate? It is
frequently interpreted as a surrogate for TP53 mutation.22
However, TP53 immunostaining does not always correlate
with mutation.37 For example, mutations resulting in deletion
or truncation of the protein will not be detected by
immunostaining. Direct comparisons of TP53 mutation and
immunohistochemistry in OA are rare and therefore the
magnitude of discrepancy between the two in oesophageal
tissue is uncertain. The few published studies involve small
numbers of cases, do not confirm mutation screening
methods by DNA sequencing, consider only exons 5–8, use
different TP53 antibodies, and define widely different cut off
points for positive staining.38–42 Nevertheless, the data do
indicate that in a proportion of cases TP53 staining will not
TP53 and progression to oesophageal adenocarcinoma 1395
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reflect mutation. However, the presence of TP53 protein can
be considered as a biomarker in its own right because other
mechanisms leading to overexpression, including accumula-
tion of wild-type TP53 in response to alterations in other
genes43 or DNA damage,44 may in themselves represent an
increased risk for disease progression. Thus we would argue
that positive TP53 immunostaining should not be interpreted
merely as a surrogate for TP53 mutation but as a more
general marker of an epithelium that is susceptible to disease
progression. In this context it is of interest that DNA damage
is elevated in Barrett’s epithelium compared with squamous
epithelium.45 This could result in inactivation of TP53,
impaired DNA repair, and clonal expansion46 47 of cells
predisposed to further genetic damage.45 48
TP53 immunostaining alone could not be employed as a
risk stratification tool on which to base entry of BO patients
into a surveillance programme because the biopsies of two
thirds of the patients who progressed to malignancy or high
grade dysplasia did not stain positively for this marker. This
contrasts with studies of tumour samples from OA patients
where the majority (.80%) have TP53 mutations.2 The
discrepancy may be because TP53 mutations occurred after
the time of biopsy collection in some patients or alternatively
TP53 independent pathways could be important in the early
stages of a subset of OA. It is possible that some of the control
subjects staining positively (diffuse/intense) for TP53 might
have progressed to low grade dysplasia during follow up.
However, as this study was not a surveillance cohort, we only
had follow up biopsies on nine control patients; only one of
these showed low grade dysplasia making it unlikely that
many progressed to dysplasia. As discussed above, TP53
status may be misclassified in some patients, either due to
sampling limitations combined with heterogeneity of TP53
alterations in the Barrett’s epithelium46 or due to the nature
of the immunohistochemical assay employed.
Absence of a relationship between cyclin D1 staining and
risk of malignancy is at odds with our previous finding in a
cohort of BO patients from Leeds, UK.23 When the data from
the NI and Leeds studies were combined, the OR for cyclin D1
staining was not significant (OR 2.21 (95% CI 0.75, 6.31)).
There are several differences between the two studies that
may account for these discrepant results. The current study
was substantially larger and was population based rather
than drawing patients from one centre, which may be
associated with some unidentified bias in recruitment.
Patients were approximately 10 years older in NI and the
mean follow up was slightly shorter; the period of time that a
BO patient had experienced undiagnosed SIM (prior to entry
in to the cohort) and the time between BO diagnosis and
cancer occurrence could possibly affect the nested case
control analysis. For example, if cyclin D1 overexpression in
the early stages following development of SIM identifies high
risk BO patients, but overexpression eventually occurs in an
increasing proportion of all BO patients, then the discrimina-
tion between cases and controls will tend to diminish with
duration of presence of SIM. In the current study, the older
age of patients and the short follow up are consistent with a
more ‘‘advanced’’ group of BO patients in the NI cohort.
These questions are difficult to resolve because the time of
onset of SIM in BO patients is unknown. No other
longitudinal studies have examined the relationship between
malignant progression in BO and cyclin D1 overexpression
but given the contrasting results to date further studies are
warranted.
COX-2 overexpression was weakly positively related to
cancer risk. Previously this relationship has been the subject
of contradictory reports.25 26 49 50 However, Abdalla and
colleagues50 reported that, independent of case control status,
COX-2 expression increased during follow up of Barrett’s
patients and gastrin was shown to be a key factor in
influencing expression. Of interest in our study was the
observation that patients who were both TP53 and COX-2
positive were at very high risk of developing malignancy but
these patients comprised only 15% of patients who developed
OA. The mechanistic role of COX-2 in BO and OA therefore
requires further study while an evaluation of COX-2 should
be conducted in larger prospective studies in combination
with other functionally related biomarkers.
b-Catenin is a key component of cell adhesion and cell
signalling pathways. However, current evidence suggests that
abnormalities in b-catenin may not play an important role in
the early stages of most OA.2 In this study, we specifically
scored nuclear accumulation of b-catenin, as an indicator of
alterations of the Wnt signalling pathway, but found nuclear
staining to be uncommon in BO. This observation is
consistent with another study where increased expression
of nuclear b-catenin occurred only in dysplastic epithelium.28
In conclusion, it is clear that immunohistochemical
detection of TP53 is a biomarker of malignant progression
in BO but alone possesses too low a sensitivity for cancer risk
for it to be applied as a criterion for endoscopic surveillance.
Detection of TP53 mutations by direct sequencing or other
screening techniques such as SSCP would potentially offer
better sensitivity and specificity compared with immunohis-
tochemistry, but such techniques are not widely available in
NHS laboratories and moreover would be difficult to adapt to
analysis of small routinely fixed and processed endoscopic
biopsies. In addition, the predictive value of TP53 immuno-
staining in the absence of genetic alterations should be
considered. Combination of TP53 status with dysplasia would
not appear to improve on its utility, as so few patients had
dysplasia. Furthermore, combining TP53 status with the
other markers examined also appears to be of limited value;
although patients who were both TP53 and COX-2 positive
were at very high risk, these patients comprised only 15% of
patients who subsequently developed cancer. Identification
of complementary biomarkers with adequate sensitivity and
specificity is therefore required to identify BO patients who
are at risk of developing cancer. Candidates will no doubt
emerge as a result of the rapid advances in screening for
markers using genomic and proteomic approaches.51 52 Such
candidate markers should be selected on the basis of what is
known about the biology of the disease and be evaluated in
appropriate study designs.21 22
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